C:\Program Files\Stnexp\Queries\10597521 (a).str





chain nodes :
7 9 10 18 19 20 27 29
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
ring/chain nodes :
8
chain bonds :
2-7 4-27 5-9 6-10 7-13 8-9 9-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-7 4-27 7-13 8-9 9-29
exact bonds :
5-9 6-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

G1:Cl,Br,F,I,[*1],[*2],[*3]

G2:H,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:Atom 20:Atom 27:CLASS 29:CLASS
Generic attributes :
18:
Saturation : Saturated
Number of Carbon Atoms : less than 7
19:
Saturation : Saturated
Number of Carbon Atoms : less than 7
20:

```
    Saturation             : Saturated
    Number of Carbon Atoms : less than 7

Element Count :
    Node 18: Limited
        C,C1-6

    Node 19: Limited
        C,C1-6
```

=>
Uploading C:\Program Files\Stnexp\Queries\10597521.str





chain nodes :
7 9 10 18 19 20 27
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
ring/chain nodes :
8
chain bonds :
2-7 4-27 5-9 6-10 7-13 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-7 4-27 7-13 8-9
exact bonds :
5-9 6-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

```
G1:Cl,Br,F,I,[*1],[*2],[*3]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  18:CLASS  19:Atom  20:Atom
27:CLASS
Generic attributes :
18:
Saturation             : Saturated
Number of Carbon Atoms : less than 7
19:
Saturation             : Saturated
Number of Carbon Atoms : less than 7
20:
Saturation             : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 18: Limited
    C,C1-6

Node 19: Limited
    C,C1-6




L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:14:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      478 TO ITERATE

100.0% PROCESSED      478 ITERATIONS                              33 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          8249 TO    10871
PROJECTED ANSWERS:              315 TO     1003

L2           33 SEA SSS SAM L1

=> =>
Uploading C:\Program Files\Stnexp\Queries\10597521 (a).str
```





chain nodes :
7 9 10 18 19 20 27 29
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
ring/chain nodes :
8
chain bonds :
2-7 4-27 5-9 6-10 7-13 8-9 9-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-7 4-27 7-13 8-9 9-29
exact bonds :
5-9 6-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

```
G1:Cl,Br,F,I,[*1],[*2],[*3]

G2:H,[*1]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  18:CLASS  19:Atom  20:Atom
27:CLASS  29:CLASS
Generic attributes :
18:
Saturation             : Saturated
Number of Carbon Atoms : less than 7
19:
Saturation             : Saturated
Number of Carbon Atoms : less than 7
20:
Saturation             : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 18: Limited
    C,C1-6

Node 19: Limited
    C,C1-6




L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 18:17:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      478 TO ITERATE

100.0% PROCESSED      478 ITERATIONS                                  8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         8249 TO    10871
PROJECTED ANSWERS:               8 TO      329

L4            8 SEA SSS SAM L3
```

```
=> => s l3 sss ful
FULL SEARCH INITIATED 18:18:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    10491 TO ITERATE

100.0% PROCESSED    10491 ITERATIONS                                184 ANSWERS
SEARCH TIME: 00.00.01

L5          184 SEA SSS FUL L3

=> => s l5
L6            2 L5

=> d l6 1-2 bib,ab,hitstr
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:201033 CAPLUS
DN 146:274347
TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
PA Anormed Inc., Can.
SO PCT Int. Appl., 363pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022371	A2	20070222	WO 2006-US32170	20060816
	WO 2007022371	A3	20071101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2619881	A1	20070222	CA 2006-2619881	20060816
	US 20070066624	A1	20070322	US 2006-505669	20060816
	EP 1924265	A2	20080528	EP 2006-813506	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009504769	T	20090205	JP 2008-527141	20060816
	IN 2008KN00797	A	20081121	IN 2008-KN797	20080222
	CN 101309690	A	20081119	CN 2006-80038097	20080414
PRAI	US 2005-708471P	P	20050816		
	WO 2006-US32170	W	20060816		

OS MARPAT 146:274347
AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926637-55-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-55-0 CAPLUS

IT 926637-54-9P 926637-84-5P 926637-85-6P
926637-86-7P 926638-32-6P 926638-33-7P
926639-19-2P 926639-48-7P 926639-51-2P
926639-52-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-54-9 CAPLUS
RN 926637-84-5 CAPLUS
RN 926637-85-6 CAPLUS
RN 926637-86-7 CAPLUS
RN 926638-32-6 CAPLUS
RN 926638-33-7 CAPLUS
RN 926639-19-2 CAPLUS
RN 926639-48-7 CAPLUS
RN 926639-51-2 CAPLUS
RN 926639-52-3 CAPLUS

IT 926642-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926642-53-7

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:962224 CAPLUS
DN 143:266945
TI Preparation of pyrimidine derivatives as cannabinoid receptor modulators
IN Eatherton, Andrew John; Giblin, Gerard Martin Paul; Mitchell, William Leonard; Naylor, Alan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005080350	A1	20050901	WO 2005-EP1939	20050221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1718620	A1	20061108	EP 2005-715508	20050221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	JP 2007523207	T	20070816	JP 2007-500151	20050221
	US 20080261977	A1	20081023	US 2006-597521	20060728
PRAI	GB 2004-3998	A	20040223		
	GB 2004-25071	A	20041112		
	WO 2005-EP1939	W	20050221		

OS CASREACT 143:266945; MARPAT 143:266945
AB The title compds. I [Y = (un)substituted Ph; R1 = H, alkyl, cycloalkyl, haloalkyl; R2 = (CH2)mR3 (wherein m = 0-1); or NR1R2 = (un)substituted 4-8 membered non-aromatic heterocyclyl; R3 = H, (un)substituted 4-8 membered non-aromatic heterocyclyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = II (wherein p =0-2; X = CH2, O, S, SO, SO2); R6 = halo, (un)substituted alkyl, cycloalkyl, etc.; R7 = OH, alkoxy, etc.; R12 = H, alkyl; with the provision], useful in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor, were prepared and formulated. Thus, reductive amination of 2-(3-chlorophenylamino)-4-cyclopropylpyrimidine-5-carbaldehyde with aminocyclobutane afforded 19% III which showed an EC50 of <300 nM and efficacy value of >50% at the cloned human cannabinoid CB2 receptor.
IT 863772-57-0P 863772-58-1P 863772-60-5P
863772-61-6P 863772-62-7P 863772-63-8P
863772-64-9P 863772-65-0P 863772-67-2P
863772-69-4P 863772-71-8P 863772-72-9P
863772-73-0P 863772-74-1P 863772-76-3P
863772-78-5P 863772-80-9P 863772-82-1P
863772-84-3P 863772-85-4P 863772-86-5P
863772-88-7P 863772-90-1P 863772-92-3P
863772-94-5P 863772-96-7P 863772-97-8P
863772-98-9P 863773-00-6P 863773-01-7P

863773-03-9P 863773-04-0P 863773-05-1P
863773-06-2P 863773-07-3P 863773-09-5P
863773-11-9P 863773-12-0P 863773-14-2P
863773-16-4P 863773-18-6P 863773-19-7P
863773-20-0P 863773-22-2P 863773-24-4P
863773-26-6P 863773-27-7P 863773-28-8P
863773-30-2P 863773-32-4P 863773-33-5P
863773-34-6P 863773-35-7P 863773-37-9P
863773-38-0P 863773-39-1P 863773-41-5P
863773-43-7P 863773-45-9P 863773-47-1P
863773-49-3P 863773-50-6P 863773-51-7P
863773-53-9P 863773-54-0P 863773-55-1P
863773-57-3P 863773-59-5P 863773-61-9P
863773-62-0P 863773-63-1P 863773-64-2P
863773-66-4P 863773-68-6P 863773-70-0P
863773-72-2P 863773-74-4P 863773-76-6P
863773-78-8P 863773-79-9P 863773-81-3P
863773-82-4P 863773-83-5P 863773-85-7P
863773-86-8P 863773-87-9P 863773-88-0P
863773-90-4P 863773-92-6P 863773-94-8P
863773-95-9P 863773-97-1P 863773-98-2P
863774-00-9P 863774-01-0P 863774-03-2P
863774-04-3P 863774-05-4P 863774-06-5P
863774-07-6P 863774-08-7P 863774-09-8P
863774-10-1P 863774-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as cannabinoid receptor modulators)

RN 863772-57-0 CAPLUS
RN 863772-58-1 CAPLUS
RN 863772-60-5 CAPLUS
RN 863772-61-6 CAPLUS
RN 863772-62-7 CAPLUS
RN 863772-63-8 CAPLUS
RN 863772-64-9 CAPLUS
RN 863772-65-0 CAPLUS
RN 863772-67-2 CAPLUS
RN 863772-69-4 CAPLUS
RN 863772-71-8 CAPLUS
RN 863772-72-9 CAPLUS
RN 863772-73-0 CAPLUS
RN 863772-74-1 CAPLUS
RN 863772-76-3 CAPLUS
RN 863772-78-5 CAPLUS
RN 863772-80-9 CAPLUS
RN 863772-82-1 CAPLUS
RN 863772-84-3 CAPLUS
RN 863772-85-4 CAPLUS
RN 863772-86-5 CAPLUS
RN 863772-88-7 CAPLUS
RN 863772-90-1 CAPLUS
RN 863772-92-3 CAPLUS
RN 863772-94-5 CAPLUS
RN 863772-96-7 CAPLUS
RN 863772-97-8 CAPLUS
RN 863772-98-9 CAPLUS

RN 863773-00-6 CAPLUS
RN 863773-01-7 CAPLUS
RN 863773-03-9 CAPLUS
RN 863773-04-0 CAPLUS
RN 863773-05-1 CAPLUS
RN 863773-06-2 CAPLUS
RN 863773-07-3 CAPLUS
RN 863773-09-5 CAPLUS
RN 863773-11-9 CAPLUS
RN 863773-12-0 CAPLUS
RN 863773-14-2 CAPLUS
RN 863773-16-4 CAPLUS
RN 863773-18-6 CAPLUS
RN 863773-19-7 CAPLUS
RN 863773-20-0 CAPLUS
RN 863773-22-2 CAPLUS
RN 863773-24-4 CAPLUS
RN 863773-26-6 CAPLUS
RN 863773-27-7 CAPLUS
RN 863773-28-8 CAPLUS
RN 863773-30-2 CAPLUS
RN 863773-32-4 CAPLUS
RN 863773-33-5 CAPLUS
RN 863773-34-6 CAPLUS
RN 863773-35-7 CAPLUS
RN 863773-37-9 CAPLUS
RN 863773-38-0 CAPLUS
RN 863773-39-1 CAPLUS
RN 863773-41-5 CAPLUS
RN 863773-43-7 CAPLUS
RN 863773-45-9 CAPLUS
RN 863773-47-1 CAPLUS
RN 863773-49-3 CAPLUS
RN 863773-50-6 CAPLUS
RN 863773-51-7 CAPLUS
RN 863773-53-9 CAPLUS
RN 863773-54-0 CAPLUS
RN 863773-55-1 CAPLUS
RN 863773-57-3 CAPLUS
RN 863773-59-5 CAPLUS
RN 863773-61-9 CAPLUS
RN 863773-62-0 CAPLUS
RN 863773-63-1 CAPLUS
RN 863773-64-2 CAPLUS
RN 863773-66-4 CAPLUS
RN 863773-68-6 CAPLUS
RN 863773-70-0 CAPLUS
RN 863773-72-2 CAPLUS
RN 863773-74-4 CAPLUS
RN 863773-76-6 CAPLUS
RN 863773-78-8 CAPLUS
RN 863773-79-9 CAPLUS
RN 863773-81-3 CAPLUS
RN 863773-82-4 CAPLUS
RN 863773-83-5 CAPLUS
RN 863773-85-7 CAPLUS
RN 863773-86-8 CAPLUS

RN 863773-87-9 CAPLUS
RN 863773-88-0 CAPLUS
RN 863773-90-4 CAPLUS
RN 863773-92-6 CAPLUS
RN 863773-94-8 CAPLUS
RN 863773-95-9 CAPLUS
RN 863773-97-1 CAPLUS
RN 863773-98-2 CAPLUS
RN 863774-00-9 CAPLUS
RN 863774-01-0 CAPLUS
RN 863774-03-2 CAPLUS
RN 863774-04-3 CAPLUS
RN 863774-05-4 CAPLUS
RN 863774-06-5 CAPLUS
RN 863774-07-6 CAPLUS
RN 863774-08-7 CAPLUS
RN 863774-09-8 CAPLUS
RN 863774-10-1 CAPLUS
RN 863774-11-2 CAPLUS
IT 863774-25-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as cannabinoid receptor modulators)
RN 863774-25-8
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d l6 1-2 bib,ab,hitstr

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:201033 CAPLUS
DN 146:274347
TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
PA Anormed Inc., Can.
SO PCT Int. Appl., 363pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022371	A2	20070222	WO 2006-US32170	20060816
	WO 2007022371	A3	20071101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2619881	A1	20070222	CA 2006-2619881	20060816
	US 20070066624	A1	20070322	US 2006-505669	20060816
	EP 1924265	A2	20080528	EP 2006-813506	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009504769	T	20090205	JP 2008-527141	20060816
	IN 2008KN00797	A	20081121	IN 2008-KN797	20080222
	CN 101309690	A	20081119	CN 2006-80038097	20080414
PRAI	US 2005-708471P	P	20050816		
	WO 2006-US32170	W	20060816		

OS MARPAT 146:274347
AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926637-55-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:201033 CAPLUS
DN 146:274347
TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
PA Anormed Inc., Can.
SO PCT Int. Appl., 363pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022371	A2	20070222	WO 2006-US32170	20060816
	WO 2007022371	A3	20071101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2619881	A1	20070222	CA 2006-2619881	20060816
	US 20070066624	A1	20070322	US 2006-505669	20060816
	EP 1924265	A2	20080528	EP 2006-813506	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009504769	T	20090205	JP 2008-527141	20060816
	IN 2008KN00797	A	20081121	IN 2008-KN797	20080222
	CN 101309690	A	20081119	CN 2006-80038097	20080414
PRAI	US 2005-708471P	P	20050816		
	WO 2006-US32170	W	20060816		

OS MARPAT 146:274347
AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

COMMAND INTERRUPTED
REENTER FILE 'CAPLUS'
AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

Your command did not complete due to a temporary system problem. To recover, reenter the file you are in now. Then, any command that is normally available to you may be used. No cost summary for the current file will be displayed. After reentering the current file you may retry your command. Also, you may wish to SAVE your search query. This can be done in any file. If you cannot access your current file, or if your command fails a second time, notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or by using the SEND command in STNMAIL file.

```
=> d l6 1-2 bib,ab,hitstr
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> => d l6 1-2 bib,ab,hitstr
IT   926637-55-0P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:201033 CAPLUS
DN 146:274347
TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
PA Anormed Inc., Can.
SO PCT Int. Appl., 363pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022371	A2	20070222	WO 2006-US32170	20060816
	WO 2007022371	A3	20071101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2619881	A1	20070222	CA 2006-2619881	20060816
	US 20070066624	A1	20070322	US 2006-505669	20060816
	EP 1924265	A2	20080528	EP 2006-813506	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009504769	T	20090205	JP 2008-527141	20060816
	IN 2008KN00797	A	20081121	IN 2008-KN797	20080222
	CN 101309690	A	20081119	CN 2006-80038097	20080414
PRAI	US 2005-708471P	P	20050816		
	WO 2006-US32170	W	20060816		

OS MARPAT 146:274347
AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926637-55-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-55-0 CAPLUS

CN Benzoic acid, 4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 926637-54-9P 926637-84-5P 926637-85-6P
926637-86-7P 926638-32-6P 926638-33-7P
926639-19-2P 926639-48-7P 926639-51-2P
926639-52-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-54-9 CAPLUS

CN Benzoic acid, 4-[[5-[[4-[(5R)-3-cyclohexyl-2-oxo-5-phenyl-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926637-84-5 CAPLUS
CN Benzamide, N-cyclopropyl-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926637-85-6 CAPLUS
CN Benzamide, N-methoxy-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926637-86-7 CAPLUS
CN Benzamide, N-(1-methylethyl)-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926638-32-6 CAPLUS
CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(3-chlorophenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926638-33-7 CAPLUS
CN Benzoic acid, 4-[[5-[[4-[5-(3-chlorophenyl)-3-cyclohexyl-2-oxo-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 926639-19-2 CAPLUS
CN Methanesulfonamide, N-[4-[[4-methyl-5-[[4-[(4R)-2-oxo-4-phenyl-3-oxazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926639-48-7 CAPLUS
CN Benzoic acid, 4-[[4-methyl-5-[[4-[(5R)-5-(3-methylphenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926639-51-2 CAPLUS
CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(2-fluoro-5-methylphenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 926639-52-3 CAPLUS
CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(3-fluorophenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 926642-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)
RN 926642-53-7 CAPLUS
CN 2-Oxazolidinone, 3-[1-[[2-[(4-aminophenyl)amino]-4-methyl-5-pyrimidinyl]methyl]-4-piperidinyl]-4-phenyl-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:962224 CAPLUS
DN 143:266945
TI Preparation of pyrimidine derivatives as cannabinoid receptor modulators
IN Eatherton, Andrew John; Giblin, Gerard Martin Paul; Mitchell, William Leonard; Naylor, Alan
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005080350	A1	20050901	WO 2005-EP1939	20050221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1718620	A1	20061108	EP 2005-715508	20050221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
	JP 2007523207	T	20070816	JP 2007-500151	20050221
	US 20080261977	A1	20081023	US 2006-597521	20060728
PRAI	GB 2004-3998	A	20040223		
	GB 2004-25071	A	20041112		
	WO 2005-EP1939	W	20050221		

OS CASREACT 143:266945; MARPAT 143:266945
AB The title compds. I [Y = (un)substituted Ph; R1 = H, alkyl, cycloalkyl, haloalkyl; R2 = (CH2)mR3 (wherein m = 0-1); or NR1R2 = (un)substituted 4-8 membered non-aromatic heterocyclyl; R3 = H, (un)substituted 4-8 membered non-aromatic heterocyclyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = II (wherein p =0-2; X = CH2, O, S, SO, SO2); R6 = halo, (un)substituted alkyl, cycloalkyl, etc.; R7 = OH, alkoxy, etc.; R12 = H, alkyl; with the provision], useful in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor, were prepared and formulated. Thus, reductive amination of 2-(3-chlorophenylamino)-4-cyclopropylpyrimidine-5-carbaldehyde with aminocyclobutane afforded 19% III which showed an EC50 of <300 nM and efficacy value of >50% at the cloned human cannabinoid CB2 receptor.
IT 863772-57-0P 863772-58-1P 863772-60-5P
863772-61-6P 863772-62-7P 863772-63-8P
863772-64-9P 863772-65-0P 863772-67-2P
863772-69-4P 863772-71-8P 863772-72-9P
863772-73-0P 863772-74-1P 863772-76-3P
863772-78-5P 863772-80-9P 863772-82-1P
863772-84-3P 863772-85-4P 863772-86-5P
863772-88-7P 863772-90-1P 863772-92-3P
863772-94-5P 863772-96-7P 863772-97-8P
863772-98-9P 863773-00-6P 863773-01-7P

863773-03-9P 863773-04-0P 863773-05-1P
863773-06-2P 863773-07-3P 863773-09-5P
863773-11-9P 863773-12-0P 863773-14-2P
863773-16-4P 863773-18-6P 863773-19-7P
863773-20-0P 863773-22-2P 863773-24-4P
863773-26-6P 863773-27-7P 863773-28-8P
863773-30-2P 863773-32-4P 863773-33-5P
863773-34-6P 863773-35-7P 863773-37-9P
863773-38-0P 863773-39-1P 863773-41-5P
863773-43-7P 863773-45-9P 863773-47-1P
863773-49-3P 863773-50-6P 863773-51-7P
863773-53-9P 863773-54-0P 863773-55-1P
863773-57-3P 863773-59-5P 863773-61-9P
863773-62-0P 863773-63-1P 863773-64-2P
863773-66-4P 863773-68-6P 863773-70-0P
863773-72-2P 863773-74-4P 863773-76-6P
863773-78-8P 863773-79-9P 863773-81-3P
863773-82-4P 863773-83-5P 863773-85-7P
863773-86-8P 863773-87-9P 863773-88-0P
863773-90-4P 863773-92-6P 863773-94-8P
863773-95-9P 863773-97-1P 863773-98-2P
863774-00-9P 863774-01-0P 863774-03-2P
863774-04-3P 863774-05-4P 863774-06-5P
863774-07-6P 863774-08-7P 863774-09-8P
863774-10-1P 863774-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as cannabinoid receptor modulators)

RN 863772-57-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-cyclopropyl- (CA INDEX NAME)



RN 863772-58-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopropyl-4-(1-methylethyl)- (CA INDEX NAME)



RN 863772-60-5 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-cyclopropyl-N-(cyclopropylmethyl)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 863772-59-2
CMF C18 H21 Cl N4



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 863772-61-6 CAPLUS
CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-cyclopropyl-5-(4-morpholinylmethyl)- (CA INDEX NAME)



RN 863772-62-7 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-cyclopropyl-N-(2-methylpropyl)- (CA INDEX NAME)



RN 863772-63-8 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1-methylethyl)-5-(4-morpholinylmethyl)- (CA INDEX NAME)



RN 863772-64-9 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclopropylmethyl)-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863772-65-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863772-67-2 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methoxyethyl)-4-(1-methylethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-66-1
CMF C17 H23 Cl N4 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863772-69-4 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-68-3
CMF C18 H20 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-71-8 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-70-7
CMF C16 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-72-9 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclohexylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863772-73-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chloro-4-fluorophenyl)amino]-N-(cyclopropylmethyl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863772-74-1 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863772-76-3 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-75-2
CMF C18 H20 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-78-5 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(tetrahydro-2H-pyran-4-yl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-77-4
CMF C17 H18 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-80-9 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methoxyethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-79-6
CMF C15 H16 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-82-1 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclobutylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-81-0
CMF C17 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-84-3 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-propyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-83-2
CMF C15 H16 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-85-4 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(2,2-dimethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863772-86-5 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863772-88-7 CAPLUS
CN Formic acid, compd. with N-butyl-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-87-6
CMF C16 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-90-1 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-cyclopropyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-89-8
CMF C15 H14 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-92-3 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(3-methylbutyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-91-2
CMF C17 H20 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863772-94-5 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopropylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-93-4
CMF C16 H16 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-96-7 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-95-6
CMF C17 H18 Cl F3 N4 O2 S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863772-97-8 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-N-(2-methylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863772-98-9 CAPLUS
CN 5-Pyrimidinemethanamine, N-(cyclopropylmethyl)-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-00-6 CAPLUS
CN Formic acid, compd. with N-(cyclobutylmethyl)-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-99-0
CMF C17 H17 Cl2 F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-01-7 CAPLUS
CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-03-9 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-02-8
CMF C18 H15 Cl F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-04-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-N-(2,2-dimethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-05-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-N-(2-methoxyethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-06-2 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopentyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-07-3 CAPLUS
CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-09-5 CAPLUS
CN Formic acid, compd. with 2-[(3-fluorophenyl)amino]-N-(2-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-08-4
CMF C16 H18 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-11-9 CAPLUS
CN Formic acid, compd. with N-(cyclobutylmethyl)-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-10-8
CMF C17 H18 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-12-0 CAPLUS
CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-14-2 CAPLUS
CN Formic acid, compd. with N-(3-chlorophenyl)-5-(1-piperidinylmethyl)-4-(trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-13-1
CMF C17 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-16-4 CAPLUS
CN Formic acid, compd. with N-(3-chlorophenyl)-5-(1-pyrrolidinylmethyl)-4-(trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-15-3
CMF C16 H16 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-18-6 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-17-5

CMF C19 H15 Cl F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-19-7 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-20-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclohexyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-22-2 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N,N-dimethyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-21-1
CMF C14 H14 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-24-4 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-phenylethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-23-3
CMF C20 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-26-6 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(3-phenylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-25-5
CMF C21 H20 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-27-7 CAPLUS
CN 5-Pyrimidinemethanamine, N-butyl-2-[(3-chlorophenyl)amino]-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-28-8 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(1-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 1006606-92-3
CMF C16 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 863773-30-2 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[[(2R)-tetrahydro-2-furanyl]methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-29-9
CMF C17 H18 Cl F3 N4 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 863773-32-4 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[[(2S)-tetrahydro-2-furanyl]methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-31-3
CMF C17 H18 Cl F3 N4 O

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-33-5 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclobutylmethyl)-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-34-6 CAPLUS
CN 2-Propanol, 1-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]- (CA INDEX NAME)



RN 863773-35-7 CAPLUS
CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-5-(1-pyrrolidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-37-9 CAPLUS
CN Formic acid, compd. with N-(cyclopropylmethyl)-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-36-8
CMF C16 H16 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-38-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-fluorophenyl)amino]-N-(3-methylbutyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-39-1 CAPLUS
CN 2-Pyrimidinamine, N-(3-fluorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-41-5 CAPLUS
CN Formic acid, compd. with N-(2,2-dimethylpropyl)-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-40-4
CMF C17 H20 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-43-7 CAPLUS
CN Formic acid, compd. with 3-[[5-[(cyclopropylamino)methyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-42-6
CMF C16 H14 F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-45-9 CAPLUS
CN Formic acid, compd. with 3-[[5-[[(2-methylpropyl)amino]methyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-44-8
CMF C17 H18 F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-47-1 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-cyclohexyl-N-methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-46-0
CMF C19 H22 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-49-3 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-48-2
CMF C20 H18 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-50-6 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N,N-dipropyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-51-7 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(1-methylethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-53-9 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(1-methyl-4-piperidinyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-52-8
CMF C18 H21 Cl F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-54-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 863773-55-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(4-piperidinylmethyl)-4-(trifluoromethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 863773-57-3 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-ethylbutyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-56-2
CMF C18 H22 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-59-5 CAPLUS
CN Formic acid, compd. with N2-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-N1,N1-dimethyl-1,2-ethanediamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-58-4
CMF C16 H19 Cl F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-61-9 CAPLUS
CN Formic acid, compd. with N3-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-N1,N1-dimethyl-1,3-propanediamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-60-8
CMF C17 H21 Cl F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-62-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-63-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(1-ethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-64-2 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(3,3-dimethylbutyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-66-4 CAPLUS
CN Formic acid, compd. with 1-[[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]methyl]cyclohexanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-65-3
CMF C19 H22 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-68-6 CAPLUS
CN Formic acid, compd. with 2-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]ethanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-67-5
CMF C14 H14 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-70-0 CAPLUS
CN Formic acid, compd. with N-[2-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]ethyl]acetamide (1:1) (CA INDEX NAME)

CM 1

CRN 863773-69-7
CMF C16 H17 Cl F3 N5 O



CM 2

CRN 64-18-6

CMF C H2 O2



RN 863773-72-2 CAPLUS
CN Formic acid, compd. with 2-[(3-fluorophenyl)amino]-N-(1-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-71-1
CMF C16 H18 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-74-4 CAPLUS
CN Formic acid, compd. with 3-[[5-(4-morpholinylmethyl)-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-73-3
CMF C17 H16 F3 N5 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-76-6 CAPLUS
CN Formic acid, compd. with 3-[[5-[[(cyclopropylmethyl)amino]methyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-75-5
CMF C17 H16 F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-78-8 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(6-methoxy-3-pyridinyl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-77-7
CMF C19 H17 Cl F3 N5 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-79-9 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-81-3 CAPLUS
CN Formic acid, compd. with N-(3-chlorophenyl)-5-[(4-methyl-1-piperazinyl)methyl]-4-(trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-80-2
CMF C17 H19 Cl F3 N5



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-82-4 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-[1-(4-fluorophenyl)ethyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-83-5 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N,N-bis(2-methoxyethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-85-7 CAPLUS
CN Formic acid, compd. with 1-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-4-piperidinemethanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-84-6
CMF C18 H20 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863773-86-8 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopropyl-α-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-87-9 CAPLUS
CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(3-fluorophenyl)amino]-α-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-88-0 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-fluorophenyl)amino]-α-methyl-N-(2-methylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-90-4 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-α-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-89-1
CMF C19 H22 Cl F3 N4 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-92-6 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclohexylmethyl)-α-methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-91-5
CMF C20 H24 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-94-8 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-α-methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-93-7
CMF C19 H22 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-95-9 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-α-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863773-97-1 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-α-methyl-N-(2-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-96-0
CMF C17 H20 Cl F3 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863773-98-2 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-5-[1-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863774-00-9 CAPLUS
CN Formic acid, compd. with N-(cyclopropylmethyl)-2-[(3-fluorophenyl)amino]-

α-methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-99-3
CMF C17 H18 F4 N4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 863774-01-0 CAPLUS
CN 5-Pyrimidinemethanamine, N-(cyclohexylmethyl)-2-[(2,4-dichlorophenyl)amino]-α-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 863774-03-2 CAPLUS
CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863774-02-1
CMF C18 H14 Cl F4 N5



CM 2

CRN 64-18-6
CMF C H2 O2

RN 863774-04-3 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1,1-dimethylethyl)-5-(4-morpholinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863774-05-4 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863774-06-5 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863774-07-6 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-[(4-fluorophenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863774-08-7 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-(2-methoxyethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 863774-09-8 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 863774-10-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclopropylmethyl)-4-(1,1-dimethylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 863774-11-2 CAPLUS
CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1-methylethyl)-5-(1-piperazinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



IT 863774-25-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine derivs. as cannabinoid receptor modulators)
RN 863774-25-8 CAPLUS
CN Carbamic acid, [[2-[(3-chloro-4-fluorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl](cyclopropylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    12.28     212.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.64      -3.28

STN INTERNATIONAL LOGOFF AT 18:24:06 ON 26 MAR 2009
```